A modern organism genetically modified to display extinct traits
More than two centuries after the last blue antelope disappeared from the Cape of South Africa, a Dallas biotechnology company is attempting to reverse that loss using preserved museum DNA and the tools of genomic editing. Colossal Biosciences, already known for its efforts to revive the woolly mammoth and the dire wolf, has entered the active phase of reconstructing the bluebuck's genome, with surrogate births projected within years. The project forces a quiet reckoning with what humanity owes to species it erased, and whether science can truly restore what history has undone — or only approximate it.
- Colossal Biosciences has moved beyond planning and into active genomic editing, introducing bluebuck genetic sequences into living roan antelope cells as the first concrete step toward a birth.
- The scientific community is sharply divided: critics argue the resulting animal would be a genetically modified roan antelope wearing extinct traits, not a genuine resurrection of a lost species.
- The landscape the bluebuck once roamed has been transformed beyond recognition over two centuries, raising serious doubts about whether any reintroduction into southern Africa could succeed ecologically.
- Defenders of the project point to a broader payoff — reproductive and genetic technologies developed for the bluebuck could directly aid 29 threatened antelope species facing extinction right now.
- With $555 million raised and high-profile backers, Colossal is betting that de-extinction can be both scientifically credible and commercially viable, but the true measure remains what survives in the field.
Uma empresa de biotecnologia em Dallas está tentando fazer o que parecia impossível: trazer de volta um animal extinto há mais de dois séculos. A Colossal Biosciences anunciou que está recriando o antílope-azul africano, desaparecido por volta de 1800, usando DNA preservado de um espécime de museu e técnicas de edição genética aplicadas a um parente vivo. O projeto já entrou na fase de edição genômica, com os primeiros animais esperados para nascer nos próximos anos.
O antílope-azul, também conhecido como bluebuck, habitava a região do Cabo, na atual África do Sul, e tem a triste distinção de ter sido o primeiro grande mamífero africano a desaparecer na história registrada. Caça, expansão colonial e perda de habitat eliminaram uma população já confinada a uma faixa estreita de território. Para reconstruir seu genoma, os cientistas da Colossal obtiveram material genético principalmente de uma pele preservada de um jovem macho no Museu de História Natural da Suécia, em Estocolmo, comparando-o com o DNA do antílope-roano como referência. O próximo passo envolve criar embriões em laboratório e implantá-los em fêmeas de roano, que atuariam como mães substitutas.
A empresa enquadra o projeto não apenas como gesto simbólico, mas como plataforma para desenvolver tecnologias que beneficiem espécies de antílopes ameaçadas. Das cerca de 90 espécies de antílopes no mundo, 29 estão ameaçadas de extinção e 55 têm populações em declínio. Técnicas de reprodução assistida e bancos genéticos desenvolvidos para o bluebuck poderiam apoiar esforços de conservação para espécies como o hirola, a gazela-dama e o adax.
No entanto, a comunidade científica permanece dividida. Críticos argumentam que um animal criado por edição genética seria um organismo moderno modificado para exibir traços extintos, não uma verdadeira recriação da espécie original. Há também a questão do encaixe ecológico: a paisagem que sustentava o antílope-azul foi profundamente transformada, e muitos pesquisadores questionam se os recursos investidos não seriam mais eficazes na proteção de espécies vivas em risco imediato.
Fundada em 2021 por Ben Lamm e pelo geneticista de Harvard George Church, a Colossal captou US$ 555 milhões até setembro de 2025 e expandiu seu portfólio para incluir pássaros, marsupiais e mamíferos extintos. Para o antílope-azul, a empresa afirma trabalhar com parceiros de conservação e planejar uma eventual reintrodução no sul da África. Mas o impacto real do projeto será determinado não pelos anúncios, e sim pelo que de fato acontecer no campo.
A biotechnology company in Dallas is attempting something that seemed impossible just years ago: bringing back an animal that vanished from Earth more than two centuries ago. Colossal Biosciences has announced it is recreating the blue antelope, an African species that went extinct around 1800, using preserved DNA from a museum specimen and genetic editing techniques applied to a living relative. The company says the project has already moved into the genomic editing phase, with the first animals expected to be born within the next several years.
The blue antelope, also known as the bluebuck, once roamed the Cape region of what is now South Africa. It holds a grim distinction: it was the first large African mammal to vanish in recorded history. The causes were familiar ones—hunting, colonial expansion, habitat loss, and competition for grazing land—pressures that overwhelmed a population already confined to a narrow range. By 1800, the species was gone.
To reconstruct the animal's genome, Colossal's scientists obtained genetic material primarily from a preserved skin of a young male housed in the Swedish Museum of Natural History in Stockholm. Researchers compared the bluebuck's DNA sequences with those of living antelopes, focusing especially on the roan antelope, which serves as the genetic reference point for the laboratory work. This comparison allows the team to identify which genetic variants correspond to the extinct animal's distinctive physical traits: its blue-gray coat, the pale marking above its eyes, and its long, curved horns. Ben Lamm, the company's CEO and cofounder, told Reuters that the project has reached the stage where bluebuck genes are being introduced into roan antelope cells. The next steps involve creating embryos in the laboratory and implanting them into female roan antelopes, which would serve as surrogate mothers during a gestation period of roughly nine months.
Colossal frames the bluebuck project not merely as a symbolic gesture but as a platform for developing technologies that could benefit living antelope species facing extinction. The company has already advanced techniques for collecting eggs from roan antelopes and creating induced pluripotent stem cells—a method that reprograms adult cells into a more versatile state. These protocols could support assisted reproduction, genetic banking, and the recovery of genetic diversity in small or fragmented populations. The numbers underscore the urgency: of roughly 90 antelope species worldwide, 29 are threatened with extinction and 55 have declining populations. In Africa, species like the hirola, the dama gazelle, and the addax face particularly dire circumstances, squeezed by habitat loss, hunting, human pressure, and population fragmentation.
Yet the scientific community remains divided on whether de-extinction projects represent genuine species restoration or something else entirely. Critics argue that an animal created through genetic editing would be a modern organism genetically modified to display traits of an extinct species, not a true recreation of the original animal. This debate intensified after Colossal announced its dire wolf project, when experts pointed out that the resulting animals would essentially be gray wolves altered to exhibit characteristics associated with the extinct species. There is also the question of ecological fit: the landscape that once supported the blue antelope has been transformed over more than two centuries of human occupation and environmental change. Even researchers who acknowledge the technical merit of the work worry about resource allocation. Many living species face immediate extinction risk and depend on habitat protection, enforcement, and controlled breeding—interventions that have proven effective. The reclassification of the scimitar-horned oryx from extinct in the wild to endangered by the IUCN in December 2023 demonstrates that traditional conservation methods still carry weight.
Colossal itself was founded in 2021 by Lamm and Harvard geneticist George Church, initially focused on creating genetically modified Asian elephants with woolly mammoth traits. The company has since expanded to include extinct birds, marsupials, and mammals, combining ancient DNA sequencing, genetic editing, cloning, and assisted reproduction. In September 2025, Colossal announced it had raised $555 million in total funding, including a $120 million round tied to its dodo program. High-profile investors include filmmaker Peter Jackson, along with venture funds and groups focused on technology, bioscience, and innovation. For the blue antelope, Colossal says it is working with conservation partners and planning eventual reintroduction in areas aligned with the species' historical range in southern Africa.
But the timeline remains uncertain. Success depends on completing the genetic edits, producing viable embryos, implanting them in surrogate mothers, and ensuring the offspring survive after birth. The bluebuck project sits at the intersection of cutting-edge science, biotechnology marketing, and practical conservation. Its real impact will be determined not by announcements but by what actually happens in the field.
Notable Quotes
The project has reached the stage where bluebuck genes are being introduced into roan antelope cells, with embryos to follow and implantation in surrogate mothers expected within years.— Ben Lamm, CEO of Colossal Biosciences, to Reuters
Technologies developed for the bluebuck could support assisted reproduction, genetic banking, and recovery of genetic diversity in small or fragmented populations of living antelope species.— Colossal Biosciences
The Hearth Conversation Another angle on the story
Why resurrect a species that's been gone for two hundred years when so many living antelopes are on the brink right now?
That's the question that divides the field. Colossal argues that the technologies they develop for the bluebuck—egg collection, stem cell work, genetic banking—can be applied to endangered species alive today. But critics say the company is spending enormous resources on a symbolic gesture when those same resources could directly protect habitat or fund breeding programs for species that still exist.
So the blue antelope itself might not be the real goal?
Not entirely. The company frames it as a proof of concept. If they can resurrect a species from museum DNA, the thinking goes, they've demonstrated tools that could save species we still have time to save. But there's a credibility problem: they're asking the world to trust that de-extinction is about conservation when it also generates headlines and attracts investors.
What would a recreated blue antelope actually be?
That's the core disagreement. Colossal would say it's the blue antelope—genetically reconstructed from ancient DNA. Critics say it's a roan antelope with edited genes that make it look like a bluebuck. The original animal evolved in a specific environment over millennia. This one would be born into a landscape that's been transformed by two centuries of human activity. It wouldn't be the same creature, even if the genes matched.
Has de-extinction ever actually worked?
Not yet, not in the way Colossal describes. They haven't produced a living animal from any of their projects. The company has announced progress—embryos, genetic edits, partnerships—but no births, no reintroductions, no proof that these animals can survive in the wild. That's still years away, if it happens at all.
What would success actually look like?
A bluebuck born from a surrogate mother that survives, reproduces, and thrives in a protected area in South Africa. But even then, you'd have to ask: is this a restored species or a laboratory creation? And did the resources spent here prevent other extinctions that could have been prevented more cheaply?